LIAN

LianBio [LIAN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

LIAN Stock Summary

Top 10 Correlated ETFs

LIAN


Top 10 Correlated Stocks

LIAN


In the News

04:15 29 Sep 2023 LIAN

LianBio to Participate in Upcoming Investor Conferences

SHANGHAI, China and PRINCETON, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor conferences:

12:02 29 Sep 2023 LIAN

LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China

As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.

09:33 29 Sep 2023 LIAN

Penny Stocks To Buy Now? 6 To Watch With Big News Today

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

11:24 29 Sep 2023 LIAN

Best Penny Stocks To Buy Now? 4 To Watch As APE Stock Goes Public

Hot penny stocks to watch but are they a buy now or not? Let's look at the catalysts.

11:41 29 Sep 2023 LIAN

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market

07:22 29 Sep 2023 LIAN

LianBio Stock (LIAN): Why The Price Surged Today

The stock price of LianBio (NASDAQ: LIAN) increased by 19.67% today. This is why it happened.

06:33 29 Sep 2023 LIAN

Medical Device Maker Highlights China Risk As Chinese U.S. IPOs Resume

Meihua International files updated prospectus highlighting China oversight risk in latest filing for its modest $57 million U.S. IPO.

12:31 29 Sep 2023 LIAN

China-U.S. IPO Pipeline Creaks Back To Life With 2 New Listing Plans

Two Chinese companies, drug maker LianBio and hotel operator Atour, are moving ahead with U.S. IPOs after a three-month pause on such listings.

LIAN Financial details

Company Rating
Neutral
Market Cap
160.75M
Income
-85.84M
Revenue
0
Book val./share
2.07
Cash/share
2.49
Dividend
-
Dividend %
-
Employees
163
Optionable
No
Shortable
Yes
Earnings
10 Nov 2023
P/E
-1.86
Forward P/E
-
PEG
0.22
P/S
-
P/B
0.72
P/C
0.6
P/FCF
-1.88
Quick Ratio
12.4
Current Ratio
12.62
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.79
EPS next Y
-
EPS next Q
-
EPS this Y
-82.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-9.09%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
74.32%
Inst Trans
-0.69%
ROA
-31%
ROE
-35%
ROC
-0.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
107.17M
Shs Float
43.24M
-
-
-
-
Target Price
-
52W Range
1.07-2.9
52W High
-25.01%
52W Low
+49.99%
RSI
34
Rel Volume
0.2
Avg Volume
212.39K
Volume
42.5K
Perf Week
-0.01%
Perf Month
-18.92%
Perf Quarter
-25.01%
Perf Half Y
-9.1%
-
-
-
-
Beta
-
-
-
Volatility
0.01%, 0.14%
Prev Close
0.66%
Price
1.4999
Change
-0.54%

LIAN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0000
Net income per share
0-1.33-5.71-1.02
Operating cash flow per share
0-0.93-4.77-0.92
Free cash flow per share
0-0.94-4.79-0.94
Cash per share
02.4211.142.8
Book value per share
0-1.2610.282.41
Tangible book value per share
0-0.9311.262.72
Share holders equity per share
0-1.2610.282.41
Interest debt per share
00.020.15-0.1
Market cap
01.44B211.87M176.99M
Enterprise value
-42.77M1.19B-11.48M102.11M
P/E ratio
0-10.33-1.08-1.6
Price to sales ratio
0000
POCF ratio
0-14.69-1.29-1.78
PFCF ratio
0-14.56-1.28-1.75
P/B Ratio
0-10.860.60.68
PTB ratio
0-10.860.60.68
EV to sales
0000
Enterprise value over EBITDA
0-8.830.06-0.81
EV to operating cash flow
0-12.120.07-1.03
EV to free cash flow
0-12.010.07-1.01
Earnings yield
0-0.1-0.93-0.62
Free cash flow yield
0-0.07-0.78-0.57
Debt to equity
-0.03-0.010.010.02
Debt to assets
0.010.010.010.01
Net debt to EBITDA
01.871.140.6
Current ratio
12.9644.4526.4813.24
Interest coverage
00-804.818.51
Income quality
00.70.840.9
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0000
Research and developement to revenue
0000
Intangibles to total assets
0000
Capex to operating cash flow
00.010.010.02
Capex to revenue
0000
Capex to depreciation
0-11.66-1.8-1.83
Stock based compensation to revenue
0000
Graham number
06.1436.337.44
ROIC
01.04-0.54-0.47
Return on tangible assets
0-0.5-0.46-0.34
Graham Net
0-1.0210.052.57
Working capital
40M270.52M384.56M289.16M
Tangible asset value
-14.82M-98.07M387.34M293.65M
Net current asset value
-15.35M-100.61M360.64M286.46M
Invested capital
-0.03-0.010.010.02
Average receivables
010.13M13.15M3.91M
Average payables
02.16M3.78M2.34M
Average inventory
00-3.02M-3.02M
Days sales outstanding
0000
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
0000
Inventory turnover
0000
ROE
01.05-0.56-0.42
Capex per share
0-0.01-0.03-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
00000
Net income per share
-0.39-0.2-0.17-0.22-0.2
Operating cash flow per share
-0.37-0.15-0.28-0.16-0.18
Free cash flow per share
-0.37-0.16-0.29-0.16-0.18
Cash per share
3.052.882.82.672.49
Book value per share
2.712.522.42.252.07
Tangible book value per share
3.022.832.722.562.38
Share holders equity per share
2.712.522.42.252.07
Interest debt per share
0.060.06-0.070.010.03
Market cap
233.11M216.71M177.33M210.04M244.33M
Enterprise value
104.24M142.61M102.45M111.62M143.58M
P/E ratio
-1.37-2.47-2.43-2.18-2.83
Price to sales ratio
00000
POCF ratio
-5.92-13.57-5.77-11.91-12.65
PFCF ratio
-5.87-12.82-5.73-11.9-12.62
P/B Ratio
0.80.790.680.871.1
PTB ratio
0.80.790.680.871.1
EV to sales
00000
Enterprise value over EBITDA
-2.42-5.88-3.5-4.35-5.73
EV to operating cash flow
-2.65-8.93-3.34-6.33-7.43
EV to free cash flow
-2.62-8.44-3.31-6.32-7.41
Earnings yield
-0.18-0.1-0.1-0.11-0.09
Free cash flow yield
-0.17-0.08-0.17-0.08-0.08
Debt to equity
0.020.020.020.020.01
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
33.052.563.844.02
Current ratio
15.814.7213.2411.4212.62
Interest coverage
-78.01-17.472.4210.990
Income quality
0.930.731.680.730.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.010.060.0100
Capex to revenue
00000
Capex to depreciation
-2.38-3.35-0.74-0.06-0.15
Stock based compensation to revenue
00000
Graham number
4.893.383.023.373.06
ROIC
-0.14-0.09-0.11-0.11-0.11
Return on tangible assets
-0.11-0.06-0.06-0.08-0.08
Graham Net
2.692.532.572.422.28
Working capital
321.96M302.21M289.16M270.13M251.46M
Tangible asset value
326.2M306.6M293.65M274.43M255.51M
Net current asset value
298.09M278.99M286.46M267.89M249.81M
Invested capital
0.020.020.020.020.01
Average receivables
9.04M9.18M5.63M2.86M2.49M
Average payables
4.58M1.63M1.74M3.44M3.67M
Average inventory
000-1.98M-1.98M
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.14-0.08-0.07-0.1-0.1
Capex per share
0-0.01000

LIAN Frequently Asked Questions

What is LianBio stock symbol ?

LianBio is a US stock , located in Princeton of Nj and trading under the symbol LIAN

What is LianBio stock quote today ?

LianBio stock price is $1.4999 today.

Is LianBio stock public?

Yes, LianBio is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap